WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Regulatory

  • Broker Dealer
  • Capital Markets
  • Corporate Governance
  • Emerging Companies
  • Employee Benefits and Compensation
  • Energy and Infrastructure
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Investment Adviser
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Activism
  • Tax and Tax Equity
  • U.S. Expansion

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • Distributed Generation, Energy Efficiency and Storage, and Microgrids
  • Energy Regulation
  • Project Development and Transactions

  • U.S. Expansion Library and Resources

  • Patents and Innovations
  • Post-Grant Review
  • Technology Transactions
  • Trademark and Copyright

  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • National Security
  • Privacy and Cybersecurity

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Merger Clearance
  • Antitrust Litigation
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Technology
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Energy
  • Financial Services
  • FoodTech and AgTech
  • Fintech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • Semiconductors
  • Software

  • Offices
  • Events
  • Pro Bono
  • Community
  • Our Diversity
  • Our Values
  • Board of Directors
  • Management Team
  • Executive Advisory Program

  • Austin
  • Beijing
  • Boston
  • Brussels
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • SOMA
  • Washington, D.C.
  • Wilmington, DE

  • Attorney Recruiting
  • Professional Staff
  • Recruiting Contacts

  • Experienced Attorneys
  • Law Students

  • Apply Online
  • Associates Committee
  • Benefits Snapshot
  • Career Management Center
  • Compensation and Benefits
  • Contacts
  • Launch
  • Mentoring and Feedback
  • NALP Forms
  • Training and Development
  • Work Assignments
  • Your School Alumni

  • Contacts
  • First Year Academy
  • Launch
  • NALP Forms
  • Summer Program
  • Tech Degrees
  • Join a Winning Team
  • Law School Recruiting
  • Your School Alumni

  • Current Openings
  • Employee Benefits Summary
  • Patent Agents & Scientific Advisors

A World-ClassAntitrust Practice.

Wilson Sonsini has "perhaps the best antitrust and competition practice for high-tech matters in the world." -- Global Competition Review

Wilson Sonsini Goodrich & Rosati's legacy closely traces the birth and evolution of Silicon Valley.

For nearly six decades, Wilson Sonsini has represented the technology pioneers associated with virtually every milestone innovation.

Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.

Read More About Us
Quick Links
  • Our Commitment to Community and Change
  • COVID-19 Client Advisory Resource
  • Find the right attorney

We advise management teams, directors, and special board or management committees on their most important and sensitive matters.

About Our Corporate Governance Practice
Careers

We look for the best and brightest of tomorrow and develop careers from the ground up.

  • Attorney Recruiting
  • Professional Staff
  • Contacts

News and Featured Insights

Client Highlights
Council of the EU Adopts Its Text on the ePrivacy Regulation
Press Releases
Brent Snyder Joins Antitrust Practice at Wilson Sonsini Goodrich & Rosati
Alerts
Virginia Legislature Sends Novel Privacy Law to Governor's Desk
Leading Matters
Client Highlights
Wilson Sonsini Advises NightDragon Acquisition Corp. on Initial Public Offering
On March 4, 2021, NightDragon Acquisition Corp. announced the closing of its initial public offering of 34,500,000 SCALE (Stakeholder-Centered Aligned Listed Equity) units, including 4,500,000 SCALE units pursuant to the full exercise of the underwriters’ over-allotment option. Each SCALE unit consists of one share of the company’s Class A common stock and one-fifth of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. The SCALE units were sold at an offering price of $10.00 per SCALE unit, generating gross proceeds of $345,000,000. The SCALE units began trading on Nasdaq on March 2, 2021, under the symbol “NDACU,” and when the securities comprising the SCALE units begin separate trading, the Class A common stock and warrants are expected to be listed on Nasdaq under the symbols “NDAC” and “NDACW,” respectively. Wilson Sonsini Goodrich & Rosati advised NightDragon Acquisition Corp. on the initial public offering.

NightDragon Acquisition Corp. was formed for the purpose of effecting a merger, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. While it may pursue an acquisition opportunity in any business, industry, sector, or geographical location, the company intends to focus its search on the cybersecurity, safety, security, and privacy sector. 

Morgan Stanley & Co. LLC acted as lead book-running manager and Drexel Hamilton acted as co-manager in the offering.

The Wilson Sonsini team that advised NightDragon Acquisition Corp. included the following:

Corporate
Jeff Saper
Robert Day
Bryan King
Angela Chen
James Babikian
Adam Grajewski
Jeff Buckelew
Learn More
Client Highlights
Firm Advises Janux Therapeutics on Patent Matters Related to $56 Million Series A Financing
On March 3, 2021, Janux Therapeutics, a developer of safe, effective novel immunotherapies using its proprietary Tumor Activated T Cell Engager (TRACTr) technology, announced the close of a $56 million Series A financing. The financing was led by Avalon Ventures and joined by new investors OrbiMed and RA Capital Management, as well as existing investors Bregua and Correlation Ventures. Wilson Sonsini Goodrich & Rosati advised Janux on patent matters related to the transaction.

T cell engagers are an emerging class of immunotherapies that bind to a tumor cell and recruit a patient’s T cells to eradicate tumor cells. Though T cell engagers have displayed substantial anti-tumor efficacy, existing therapies have been constrained by dose-limiting toxicities and poor pharmacokinetic profiles. Janux’s TRACTr technology is designed to overcome these limitations by integrating tumor-specific activation with crossover pharmacokinetics to produce best-in-class T cell engager therapeutics. The proceeds from the Series A financing will be used to advance Janux’s preclinical pipeline, including a TROP2-TRACTr and PSMA-TRACTr, with expected advancement of the company’s first candidate into the clinic in the first half of next year.

Wilson Sonsini has represented Janux in patent matters since the company’s inception. The team that advised Janux in the Series A financing includes Michael Hostetler, Laurie McNamara, Stephanie Dusaban Gonzales, Alicia Umpierre, and Ciara Alvarez-Malo.

For more information, please see Janux’s press release.
Learn More
Client Highlights
Wilson Sonsini Represents WuXi AppTec in Acquisition of OXGENE
On March 2, 2021, WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology, and medical device industries, announced that it has completed its acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. The acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide. Wilson Sonsini Goodrich & Rosati represented WuXi AppTec in the transaction, in collaboration with Taylor Wessing, which served as UK counsel.  

OXGENE will become a fully owned subsidiary of WuXi Advanced Therapies (WuXi ATU), WuXi AppTec’s cell and gene therapy contract testing, development, and manufacturing organization business unit. WuXi ATU's integrated platforms transform the development, testing, manufacturing, and commercialization of cell and gene therapy products and accelerate their time to market. OXGENE, which will retain its name, will be WuXi ATU's first facility in Europe and will further enhance these industry-leading capabilities.

The Wilson Sonsini team that represented WuXi AppTec in the transaction included the following:

Corporate
Barry Taylor
Kathy H. Ku
Nikkisha Smith
Rui Ke

London Corporate
Stacy Kim
Amanda Pollard
Jose Campos
Learn More
Client Highlights
Wilson Sonsini Advises Spire in Merger with NavSight Holdings, Inc.
On March 1, 2021, Spire Global, Inc., a global provider of space-based data and analytics, and NavSight Holdings Inc., a special purpose acquisition company, or SPAC, announced they have entered into a definitive merger agreement for a business combination that would result in Spire becoming a publicly listed company. Wilson Sonsini Goodrich & Rosati is advising Spire in the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Cullgen on Patent Matters Related to $50 Million Series B Financing
On February 25, 2021, Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, announced that it has closed a $50 million Series B financing (assuming exercise of warrant). In addition to receiving funding from existing Cullgen investors, five new prominent international venture capital firms also participated in the financing, including the lead investor, 3E Bioventures Capital, as well as Heights Capital Management (an affiliate of Susquehanna International Group), Octagon Capital, MSA Capital, and South China Venture Capital. The financing will support the development of Cullgen’s technology platform and internal pipeline of targeted protein degraders in oncology and other diseases.
Learn More
Client Highlights
Wilson Sonsini Advises Plume on $270 Million Series E Financing
On February 23, 2021, Plume, a software-as-a-service platform for communications service providers, announced the close of a $270 million minority investment from global venture capital and private equity firm Insight Partners. Wilson Sonsini Goodrich & Rosati advised Plume on the financing.
Learn More
See More Leading Matters
2020 Technology and Life Sciences IPO Report
Wilson Sonsini’s 2020 Technology and Life Sciences IPO Report presents analysis and data related to the pricing of 123 initial public offerings completed by U.S.-based technology and life sciences companies between January 1 and December 31, 2020. The report includes IPO filing, pricing, and value statistics for both sectors; governance and board of director details; ownership and structure factors; and defensive measure data points. It also considers concurrent private placements, indications of interest, direct listings, and special purpose acquisition companies.
Read the Report
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client/Employee Login
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Copyright © 2021 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.